Portosystemic Shunt in A Puppy Poodle and Medical Treatment: Case report

The case includes a 7-month-old puppy poodle applied to a private hospital for weakness, tremors and seizure attacks. Clinical examination findings were normal. From blood samples, biochemical parameter measurements were carried out. The values of alkaline phosphatase (ALP), alanine aminotransferase (ALT), ammonia and fasting serum bile acids were high and the blood urea nitrogen (BUN) value was low. Ultrasonographic examination, shunted vein in the liver to the vena cava caudalis, that is colour Doppler observed the extrahepatic shunt and turbulent flow in this shunted. Depending on clinical, laboratory (hemogram and biochemistry) and ultrasonographic observations, portosystemic shunt (PSS) was diagnosed and controlled one month after the treatment was recommended. The medical treatment included a hepatic formula diet (liver care), lactulose 0.5 ml/kg three times a day, metronidazole 15 mg/kg twice a day, S-adenosyl Methionine 15 mg/kg once a day, 400 international unite (IU) vitamin E once a day for 30 days. When turbulent flow is observed in the shunted vein in the liver to vena cava caudalis, ultrasound examination with color Doppler can help diagnose portosystemic shunt. After the treatment, clinical improvement was observed and clinical symptoms of hepatic encephalopathy including seizures and tremors, disappeared completely. Determination of turbulent flow with colour Doppler and decreased portal flow velocity with portal hypertension with PW-Doppler ultrasonography are important for the diagnosis of the portosystemic shunt. It was concluded that medical treatments might help before surgical treatments in portosystemic shunts

Yarım asırlık derginin son on yılı : Akbaba

Ankara : İhsan Doğramacı Bilkent Üniversitesi İktisadi, İdari ve Sosyal Bilimler Fakültesi, Tarih Bölümü, 2014.This work is a student project of the The Department of History, Faculty of Economics, Administrative and Social Sciences, İhsan Doğramacı Bilkent University.by Ünsal, Mehmet Süha

The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

Background: Although neoadjuvant chemotherapy (NCT) is widely used, it is not clear which subgroup of locally advanced non-small-cell lung cancer (NSCLC) patients should be treated with this approach, and if a particular benefit associated with NCT exists. In this study, we aimed to investigate the potential correlates of benefit from NCT in patients with NSCLC.Methods: All randomized clinical trials (RCTs) utilizing a NCT arm (without radiotherapy) versus a control arm before surgery were included for metaregression analysis. All regression analyses were weighed for trial size. Separate analyses were conducted for trials recruiting patients with different stages of disease. Previously published measures of treatment efficacy were used for the purpose of this study, regardless of being published in full text or abstract form.Results: A total of 14 RCTs, consisting of 3,615 patients, were selected. Histology, stage, various characteristics of the NCT protocol, and different trial features including trial quality score were not associated with the benefit of NCT. However, in trials of stage 3 disease only, there was a greater benefit in terms of reduction in mortality from NCT, if protocols with three chemotherapeutics were used (B = -0.18, t = -5.25, P = 0.006).Conclusions: We think that patients with stage 3 NSCLC are served better with NCT before surgery if protocols with three chemotherapy agents or equally effective combinations are used. In addition, the effect of neoadjuvant chemotherapy is consistent with regard to disease and patient characteristics. This finding should be tested in future RCTs or individual patient data meta-analyses. © 2012 Bozcuk et al.; licensee BioMed Central Ltd